We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

WIENER LABORATORIOS SAIC

Wiener Laboratorios Saic provides products focused on clinical and specialized laboratories as well as blood banks. I... read more Featured Products: More products

Download Mobile App




Chagas Urine Nanoparticle Test Correlates with Parasitemia Levels

By LabMedica International staff writers
Posted on 13 Mar 2016
Early diagnosis of reactivated Chagas disease in human immunodeficiency virus (HIV) patients could be lifesaving. More...
In Latin America, the diagnosis is made by microscopical detection of the Trypanosoma cruzi parasite in the blood, a diagnostic test that lacks sensitivity.

A novel nanotechnology based on the use of nano-porous particles that contain high affinity chemical baits (trypan blue) in the inner core is proposed for concentration and preservation of antigens in urine. This technology, known as Chagas urine nanoparticle test or Chunap, has been applied in the direct diagnosis of congenital Chagas disease with excellent agreement with standard diagnostic tests.

An international team of scientists led by those at the Universidad Peruana Cayetano Heredia (Lima, Peru) evaluated samples of 31 T. cruzi-infected HIV and 24 T. cruzi uninfected individuals from Cochabamba and Santa Cruz, in Bolivia. Confirmation of T. cruzi infection was based on positive results by two or more of the following commercial tests: Chagatest ELISA and Chagatest ELISA recombinant v 3.0 (Wienner Lab; Rosario, Argentina) and the PolyChaco indirect hemagglutination test (IHA) (Laboratorio Lemos; Buenos Aires, Argentina). Patients were asked to provide the first urine of the day before ingestion of liquids, where midstream specimens were collected. Urinalysis was done using urine test strip.

The concentration of T. cruzi antigens was accomplished using hydrogel nano-porous particles. Electrophoresis and Western Blot analysis of the antigens were performed. Antigen levels were determined by densitometry of western blots. The presence of any of the five diagnostic bands (22 kDa, 42 kDa, 58 kDa, 75 kDa, and 82 kDa) was considered as a positive result. In each experiment they included a negative control, a urine sample of healthy volunteer, and a positive control, 10 mL of healthy volunteer urine sample containing 1 ng of T. cruzi excreted-secreted antigen.

Parasitemia levels in patients with serology positive for Chagas disease were classified as follows: High parasitemia or reactivation of Chagas disease (detectable parasitemia by microscopy), moderate parasitemia (undetectable by microscopy but detectable by quantitative polymerase chain reaction (qPCR), and negative parasitemia (undetectable by microscopy and qPCR). The percentage of positive results detected by Chunap was: 7/7 (100%) in cases of reactivation, 11/12 (91.7%) in cases of moderate parasitemia, and 5/12 (41.7%) in cases of negative parasitemia. Chunap specificity was found to be 91.7%. A cut-off of greater than 105 pg was chosen to determine patients with reactivation of Chagas disease (7/7). Antigenuria levels were 36 times higher in patients with CD4+ lymphocyte counts below 200/mL. The study was published on February 26, 2016, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

Universidad Peruana Cayetano Heredia 
Wiener Lab
Laboratorio Lemos 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.